WEST Search History

DATE: Monday, July 21, 2003

Set Name side by side	Query	Hit Count	Set Name result set
DB=DWPI; PLUR=YES; OP=ADJ			
L24	Benjamin T L.in. and virus	1	L24
L23	Benjamin T L.in.	17	L23
L22	Benjuamin T L.in.	0	L22
L21	T antigen and papillomavirus	1	L21
L20	T antigen and papillomavirus.clm.	0	L20
DB=USPT; PLUR=YES; OP=ADJ			
L19	T antigen and papillomavirus.clm.	30	L19
L18	T antigen and papillomavirus	278	L18
L17	T antigen.clm.	110	L17
L16	T antigen	2486	L16
L15	"T-HR"	3	L15
L14	T-HR	3	L14
L13	tumor host range	0	L13
L12	L1 and sal	3	L12
L11	L1 and spalt	0	L11
L10	L1 and sal2	0	L10
L9	Benjamin Thomas L.in.	6	L9
L8	spalt and virus	4	L8
L7	spalt.clm.	0	L7
L6	spalt	54	L6
L5	sal	4989	L5
L4	sal2	12	L4
L3	P150.clm.	7	L3
L2	L1 and papillomavirus	11	L2
L1	Androphy.in.	13	L1

END OF SEARCH HISTORY

WEST

Generate Collection | Print

Search Results - Record(s) 11 through 20 of 30 returned.

☐ 11. Document ID: US 6063578 A

L19: Entry 11 of 30 File: USPT May 16, 2000

US-PAT-NO: 6063578
DOCUMENT-IDENTIFIER: US 6063578 A

TITLE: Dual reporter system and methods of use therefor

DATE-ISSUED: May 16, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Barbosa; Miguel	San Diego	CA		
Bilter; Graham K.	San Diego	CA		
Kovelman; Robert	La Jolla	CA		

US-CL-CURRENT: 435/6; 435/320.1, 435/366, 435/371

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

☐ 12. Document ID: US 6007806 A

L19: Entry 12 of 30 File: USPT Dec 28, 1999

US-PAT-NO: 6007806
DOCUMENT-IDENTIFIER: US 6007806 A

TITLE: Expression of a tumor-specific antigen by a recombinant vector virus and use thereof in preventive or curative treatment of the corresponding tumor

DATE-ISSUED: December 28, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Lathe; Richard	Strasbourg			FR
Kieny; Marie-Paule	Strasbourg			FR
Meneguzzi; Guerrino	Nice			FR

US-CL-CURRENT: 424/93.2; 424/93.6, 435/235.1, 435/320.1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

☐ 13. Document ID: US 5976853 A

L19: Entry 13 of 30 File: USPT Nov 2, 1999

US-PAT-NO: 5976853
DOCUMENT-IDENTIFIER: US 5976853 A

TITLE: Growth factor inducible serine/threonine phosphatase FIN13

DATE-ISSUED: November 2, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Guthridge; Mark A.	New York	NY		
Basilico; Claudio	New York	NY		

US-CL-CURRENT: 435/196; 435/195, 435/235.1, 435/252.3, 435/252.33, 435/320.1, 435/325, 536/23.1, 536/23.2, 536/23.5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

---

☐ 14. Document ID: US 5932412 A

L19: Entry 14 of 30 File: USPT Aug 3, 1999

US-PAT-NO: 5932412
DOCUMENT-IDENTIFIER: US 5932412 A

TITLE: Synthetic peptides in human papillomaviruses 1, 5, 6, 8, 11, 16, 18, 31, 33 and 56, useful in immunoassay for diagnostic purposes

DATE-ISSUED: August 3, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Dillner; Joakim	Stockholm			SE
Dillner; Lena	Stockholm			SE
Cheng; Hwee-Ming	Kuala Lumpur			MY

US-CL-CURRENT: 435/5; 435/7.1, 436/64, 436/813, 530/321, 530/325, 530/326, 530/388.4, 530/389.4

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

---

☐ 15. Document ID: US 5874089 A

L19: Entry 15 of 30 File: USPT Feb 23, 1999

US-PAT-NO: 5874089
DOCUMENT-IDENTIFIER: US 5874089 A
**** See image for Certificate of Correction ****

TITLE: Protecting against canine oral papillomavirus (copy)

DATE-ISSUED: February 23, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Schlegel; C. Richard	Rockville	MD		
Jenson; A. Bennett	Rockville	MD		
Ghim; Shin-je	Washington	DC		

US-CL-CURRENT: 424/204.1; 424/184.1, 424/186.1, 424/192.1, 424/199.1, 435/235.1, 435/320.1, 435/5, 435/69.1, 435/69.3, 536/23.72

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw. Desc | Image

---

☐ 16. Document ID: US 5858987 A

L19: Entry 16 of 30 File: USPT Jan 12, 1999

US-PAT-NO: 5858987
DOCUMENT-IDENTIFIER: US 5858987 A

TITLE: E6AP antisense constructs and methods of use

DATE-ISSUED: January 12, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Beer-Romero; Peggy L.	Arlington	MA		
Draetta; Giulio	Winchester	MA		
Rolfe; Mark	Newton Upper Falls	MA		

US-CL-CURRENT: 514/44; 435/5, 435/6, 435/91.2, 536/23.1, 536/24.3, 536/24.33, 536/24.5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw. Desc | Image

---

☐ 17. Document ID: US 5824488 A

L19: Entry 17 of 30 File: USPT Oct 20, 1998

US-PAT-NO: 5824488
DOCUMENT-IDENTIFIER: US 5824488 A
**** See image for Certificate of Correction ****

TITLE: Immortalized and malignant human prostatic cell lines

DATE-ISSUED: October 20, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Webber; Mukta M.	Eagle	MI		
Rhim; Johng S.	Potomac	MD		

US-CL-CURRENT: 435/7.23; 435/366, 435/371, 435/7.21, 435/975, 436/63, 436/64

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC
Draw Desc | Image

☐ 18. Document ID: US 5821051 A

L19: Entry 18 of 30 File: USPT Oct 13, 1998

US-PAT-NO: 5821051
DOCUMENT-IDENTIFIER: US 5821051 A

TITLE: E6 binding proteins

DATE-ISSUED: October 13, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Androphy; Elliot	Natick	MA		
Chen; Jason J.	Boston	MA		

US-CL-CURRENT: 435/5; 530/350, 530/352, 530/357, 530/358

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC
Draw Desc | Image

☐ 19. Document ID: US 5811281 A

L19: Entry 19 of 30 File: USPT Sep 22, 1998

US-PAT-NO: 5811281
DOCUMENT-IDENTIFIER: US 5811281 A

TITLE: Immortalized intestinal epithelial cell lines

DATE-ISSUED: September 22, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Quaroni; Andrea	Ithaca	NY		
Paul; Eileen C. A.	Ithaca	NY		

US-CL-CURRENT: 435/353; 435/320.1, 435/467

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC
Draw Desc | Image

☐ 20. Document ID: US 5744133 A

L19: Entry 20 of 30 File: USPT Apr 28, 1998

US-PAT-NO: 5744133
DOCUMENT-IDENTIFIER: US 5744133 A

TITLE: Expression of a tumor-specific antigen by a recombinant vector virus and use thereof in preventitive or curative treatment of the corresponding tumor

DATE-ISSUED: April 28, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Lathe; Richard	Strasbourg			FR
Kieny; Marie-Paule	Strasbourg			FR
Meneguzzi; Guerrino	Nice			FR

US-CL-CURRENT: 424/93.2; 424/93.6, 435/235.1, 435/320.1

WEST

Generate Collection | Print

Search Results - Record(s) 11 through 20 of 30 returned.

☐ 11. Document ID: US 6063578 A

L19: Entry 11 of 30 File: USPT May 16, 2000

US-PAT-NO: 6063578
DOCUMENT-IDENTIFIER: US 6063578 A

TITLE: Dual reporter system and methods of use therefor

DATE-ISSUED: May 16, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Barbosa; Miguel	San Diego	CA		
Bilter; Graham K.	San Diego	CA		
Kovelman; Robert	La Jolla	CA		

US-CL-CURRENT: 435/6; 435/320.1, 435/366, 435/371

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

☐ 12. Document ID: US 6007806 A

L19: Entry 12 of 30 File: USPT Dec 28, 1999

US-PAT-NO: 6007806
DOCUMENT-IDENTIFIER: US 6007806 A

TITLE: Expression of a tumor-specific antigen by a recombinant vector virus and use thereof in preventive or curative treatment of the corresponding tumor

DATE-ISSUED: December 28, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Lathe; Richard	Strasbourg			FR
Kieny; Marie-Paule	Strasbourg			FR
Meneguzzi; Guerrino	Nice			FR

US-CL-CURRENT: 424/93.2; 424/93.6, 435/235.1, 435/320.1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

☐ 13. Document ID: US 5976853 A

L19: Entry 13 of 30 File: USPT Nov 2, 1999

US-PAT-NO: 5976853
DOCUMENT-IDENTIFIER: US 5976853 A

TITLE: Growth factor inducible serine/threonine phosphatase FIN13

DATE-ISSUED: November 2, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Guthridge; Mark A.	New York	NY		
Basilico; Claudio	New York	NY		

US-CL-CURRENT: 435/196; 435/195, 435/235.1, 435/252.3, 435/252.33, 435/320.1, 435/325, 536/23.1, 536/23.2, 536/23.5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC
Draw. Desc | Image

☐ 14. Document ID: US 5932412 A

L19: Entry 14 of 30 File: USPT Aug 3, 1999

US-PAT-NO: 5932412
DOCUMENT-IDENTIFIER: US 5932412 A

TITLE: Synthetic peptides in human papillomaviruses 1, 5, 6, 8, 11, 16, 18, 31, 33 and 56, useful in immunoassay for diagnostic purposes

DATE-ISSUED: August 3, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Dillner; Joakim	Stockholm			SE
Dillner; Lena	Stockholm			SE
Cheng; Hwee-Ming	Kuala Lumpur			MY

US-CL-CURRENT: 435/5; 435/7.1, 436/64, 436/813, 530/321, 530/325, 530/326, 530/388.4, 530/389.4

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC
Draw. Desc | Image

☐ 15. Document ID: US 5874089 A

L19: Entry 15 of 30 File: USPT Feb 23, 1999

US-PAT-NO: 5874089
DOCUMENT-IDENTIFIER: US 5874089 A
**** See image for Certificate of Correction ****

TITLE: Protecting against canine oral papillomavirus (copy)

DATE-ISSUED: February 23, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Schlegel; C. Richard	Rockville	MD		
Jenson; A. Bennett	Rockville	MD		
Ghim; Shin-je	Washington	DC		

US-CL-CURRENT: 424/204.1; 424/184.1, 424/186.1, 424/192.1, 424/199.1, 435/235.1, 435/320.1, 435/5, 435/69.1, 435/69.3, 536/23.72

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

---

☐ 16. Document ID: US 5858987 A

L19: Entry 16 of 30 File: USPT Jan 12, 1999

US-PAT-NO: 5858987
DOCUMENT-IDENTIFIER: US 5858987 A

TITLE: E6AP antisense constructs and methods of use

DATE-ISSUED: January 12, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Beer-Romero; Peggy L.	Arlington	MA		
Draetta; Giulio	Winchester	MA		
Rolfe; Mark	Newton Upper Falls	MA		

US-CL-CURRENT: 514/44; 435/5, 435/6, 435/91.2, 536/23.1, 536/24.3, 536/24.33, 536/24.5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

---

☐ 17. Document ID: US 5824488 A

L19: Entry 17 of 30 File: USPT Oct 20, 1998

US-PAT-NO: 5824488
DOCUMENT-IDENTIFIER: US 5824488 A
**** See image for Certificate of Correction ****

TITLE: Immortalized and malignant human prostatic cell lines

DATE-ISSUED: October 20, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Webber; Mukta M.	Eagle	MI		
Rhim; Johng S.	Potomac	MD		

US-CL-CURRENT: 435/7.23; 435/366, 435/371, 435/7.21, 435/975, 436/63, 436/64

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC
Draw Desc | Image

☐ 18. Document ID: US 5821051 A

L19: Entry 18 of 30 File: USPT Oct 13, 1998

US-PAT-NO: 5821051
DOCUMENT-IDENTIFIER: US 5821051 A

TITLE: E6 binding proteins

DATE-ISSUED: October 13, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Androphy; Elliot	Natick	MA		
Chen; Jason J.	Boston	MA		

US-CL-CURRENT: 435/5; 530/350, 530/352, 530/357, 530/358

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC
Draw Desc | Image

☐ 19. Document ID: US 5811281 A

L19: Entry 19 of 30 File: USPT Sep 22, 1998

US-PAT-NO: 5811281
DOCUMENT-IDENTIFIER: US 5811281 A

TITLE: Immortalized intestinal epithelial cell lines

DATE-ISSUED: September 22, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Quaroni; Andrea	Ithaca	NY		
Paul; Eileen C. A.	Ithaca	NY		

US-CL-CURRENT: 435/353; 435/320.1, 435/467

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC
Draw Desc | Image

☐ 20. Document ID: US 5744133 A

L19: Entry 20 of 30 File: USPT Apr 28, 1998

US-PAT-NO: 5744133
DOCUMENT-IDENTIFIER: US 5744133 A

TITLE: Expression of a tumor-specific antigen by a recombinant vector virus and use thereof in preventitive or curative treatment of the corresponding tumor

DATE-ISSUED: April 28, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Lathe; Richard	Strasbourg			FR
Kieny; Marie-Paule	Strasbourg			FR
Meneguzzi; Guerrino	Nice			FR

US-CL-CURRENT: 424/93.2; 424/93.6, 435/235.1, 435/320.1

WEST

End of Result Set

Generate Collection Print

L21: Entry 1 of 1 File: DWPI Mar 9, 1988

DERWENT-ACC-NO: 1988-065987
DERWENT-WEEK: 200157

TITLE: Viral vector for controlling tumours - contg. DNA sequence for tumour specific antigen and corresponding polypeptide(s)

INVENTOR: KIENY, M; LATHE, R ; LIENY, M P ; MENEGUZZI, G

PRIORITY-DATA: 1986FR-0011700 (August 13, 1986), 1989FR-0002897 (March 6, 1989), 1990WO-FR00151 (March 6, 1990)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
EP 259212 A	March 9, 1988	F	014	
DK 173755 B	September 10, 2001		000	C12N015/37
JP 63049077 A	March 1, 1988		000	
AU 8776797 A	February 18, 1988		000	
FR 2602790 A	February 19, 1988		000	
DK 8704216 A	February 14, 1988		000	
EP 259212 B1	February 16, 1994	F	016	C12N015/00
DE 3789082 G	March 24, 1994		000	C12N015/00
ES 2061520 T3	December 16, 1994		000	C12N015/00
JP 09173061 A	July 8, 1997		008	C12N005/10
US 5744133 A	April 28, 1998		021	A01N063/00
JP 2852515 B2	February 3, 1999		010	C12N015/09
US 6007806 A	December 28, 1999		000	A01N063/00
CA 1341241 C	June 5, 2001	F	000	A61K039/12

INT-CL (IPC): A01N 63/00; A61K 35/76; A61K 37/02; A61K 39/00; A61K 39/12; A61K 39/275; C07K 14/025; C07K 15/00; C12N 5/00; C12N 5/10; C12N 7/00; C12N 7/01; C12N 7/04; C12N 15/00; C12N 15/09; C12N 15/37; C12N 15/82; C12N 15/86; C12P 21/00; G01N 33/57; G01N 33/574; C12P 21/00; C12R 1/91

ABSTRACTED-PUB-NO: EP 259212A
BASIC-ABSTRACT:

Viral vectors of the pox, adens or herpes types, contain a heterologous DNA sequence (I) coding for at least the essential regions of a tumour-sepcific protein (II; a T-antigen), plus elements necessary for expression of (II) in higher cells. Also new are (1) mammalian cells infected by these vectors; (II) obtd. by culturing infected cells and (3) antibodies raised against (II).

The vector is pref. vaccine virus and (I) codes for a protein specific for a spontaneous tumour or for a protein coded by an oncogenic virus, esp. of the papova or retro types. Pref. (I) is under control of a promoter of the host vector, e.g. that of the 7.5 K protein, and is inserted into a non-essential virus gene, esp. the TK gene. Pref. (I) is free of introns.

USE/ADVANTAGE - (II) are useful for curative and preventative treatment of tumours, and the viral vectors (alive or killed) can be used similarly. The antibodies, opt. in labelled form, are useful diagnostically.

ABSTRACTED-PUB-NO:

EP 259212B
EQUIVALENT-ABSTRACTS:

A pharmaceutical composition for the preventive or curative treatment of a tumour which comprises as therapeutical agent a viral vector chosen from amongst poxviruses, adenoviruses and viruses of the herpes group, which comprises a heterologous DNA sequence which codes at least for the essential region of a tumour-specific protein, called T antigen.

US 5744133A

The composition contains a recombinant poxvirus comprising an heterologous DNA sequence encoding at least for the essential region of a non-structual papillomavirus protein as well as the regulation elements ensuring its expression in the higher cells. The proteins are particularly E1, E2, E3 E4, E5, E6 and E7 from the HPV-16 virus.

USE/ADVANTAGE -The active vaccine may be administered by injection to humans and naimals. It is used in the therapy of papillomavirus - induced tumours. Also, for antiviral treatment in cows.

In an example demale rates were vaccinated by intradermal injection with different recombinant viruses (VVhE6 and VVE7). After several days they were inoculated with cells transformed with a plasmid containing the genome of HPV-16. Tumours developed in non-vaccinated control animals ten days after inoculation with transformed cells, whereas animals vaccinated with VVhE6 or VVhE7 did not develop tumours in most cases.

US 6007806A

The composition contains a recombinant poxvirus comprising an heterologous DNA sequence encoding at least for the essential region of a non-structual papillomavirus protein as well as the regulation elements ensuring its expression in the higher cells. The proteins are particularly E1, E2, E3 E4, E5, E6 and E7 from the HPV-16 virus.

USE/ADVANTAGE -The active vaccine may be administered by injection to humans and naimals. It is used in the therapy of papillomavirus - induced tumours. Also, for antiviral treatment in cows.

In an example demale rates were vaccinated by intradermal injection with different recombinant viruses (VVhE6 and VVE7). After several days they were inoculated with cells transformed with a plasmid containing the genome of HPV-16. Tumours developed in non-vaccinated control animals ten days after inoculation with transformed cells, whereas animals vaccinated with VVhE6 or VVhE7 did not develop tumours in most cases.

ABSTRACTED-PUB-NO: EP 259212A
EQUIVALENT-ABSTRACTS: EP 259212B A pharmaceutical composition for the preventive or curative treatment of a tumour which comprises as therapeutical agent a viral vector chosen from amongst poxviruses, adenoviruses and viruses of the herpes group, which comprises a heterologous DNA sequence which codes at least for the essential region of a tumour-specific protein, called T antigen. US 5744133A The composition contains a recombinant poxvirus comprising an heterologous DNA sequence encoding at least for the essential region of a non-structual papillomavirus protein as well as the regulation elements ensuring its expression in the higher cells. The proteins are particularly E1, E2, E3 E4, E5, E6 and E7 from the HPV-16 virus. USE/ADVANTAGE -The active vaccine may be administered by injection to humans and naimals. It is used in the therapy of papillomavirus - induced tumours. Also, for antiviral treatment in cows. In an example demale rates were vaccinated by intradermal injection with different recombinant viruses (VVhE6 and VVE7). After several days they were inoculated with cells transformed with a plasmid containing the genome of HPV-16. Tumours developed in non-vaccinated control animals ten days after inoculation with transformed cells, whereas animals vaccinated with VVhE6 or VVhE7 did not develop tumours in most cases. US 6007806A The composition contains a recombinant poxvirus comprising an heterologous

DNA sequence encoding at least for the essential region of a non-structual papillomavirus protein as well as the regulation elements ensuring its expression in the higher cells. The proteins are particularly E1, E2, E3 E4, E5, E6 and E7 from the HPV-16 virus. USE/ADVANTAGE -The active vaccine may be administered by injection to humans and naimals. It is used in the therapy of papillomavirus - induced tumours. Also, for antiviral treatment in cows. In an example demale rates were vaccinated by intradermal injection with different recombinant viruses (VVhE6 and VVE7). After several days they were inoculated with cells transformed with a plasmid containing the genome of HPV-16. Tumours developed in non-vaccinated control animals ten days after inoculation with transformed cells, whereas animals vaccinated with VVhE6 or VVhE7 did not develop tumours in most cases.

CHOSEN-DRAWING: Dwg.0/3 Dwg.0/3 Dwg.0/12

WEST

End of Result Set

Generate Collection Print

L24: Entry 1 of 1 File: DWPI Oct 24, 2002

DERWENT-ACC-NO: 2002-164637
DERWENT-WEEK: 200273

TITLE: Detecting protein involved in susceptibility to proliferative disease, by infecting normal and abnormal proliferating cells with mutant virus, detecting mutated protein allowing growth of mutant on abnormal cells

INVENTOR: BENJAMIN, T L; CRAMER, D W ; LI, D ; MA, Y ; MOK, S C

PRIORITY-DATA: 2001US-0812633 (March 19, 2001), 2000US-216723P (July 7, 2000), 2001US-0812471 (March 19, 2001), 2001US-0988117 (November 16, 2001)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 20020156039 A1	October 24, 2002		000	A01K067/27
WO 200204596 A2	January 17, 2002	E	092	C12N000/00
US 20020018765 A1	February 14, 2002		000	A61K048/00
US 20020147996 A1	October 10, 2002		000	A01K067/00

INT-CL (IPC): A01 K 67/00; A01 K 67/27; A61 K 48/00; C12 N 0/00; C12 Q 1/68; C12 Q 1/70

ABSTRACTED-PUB-NO: US20020018765A
BASIC-ABSTRACT:

NOVELTY - Identifying (M1) a cellular protein (I) involved in susceptibility to proliferative disease, comprising infecting normally (C1) and abnormally proliferating (C2) cells with a collection of uncharacterized mutant viruses, identifying a mutant virus (MV), identifying a mutated gene or protein (MP) that allow MV to grow only on C2, and identifying (I) that interacts only with wild-type protein, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

(1) a tumor host range (T-HR) virus (II) isolated by M1;

(2) determining (M2) the presence or absence of an alteration in the genetic material of a cell by determining if a cell can act as a permissive host for the propagation of a characterized T-HR mutant (a tumor host range mutant viruses which are able to propagate only in abnormally proliferating cells);

(3) identifying (M3) a mammal having or at increased risk of acquiring a proliferative disease, by determining alteration in Sal2 nucleic acid or protein, of the mammal;

(4) a knockout mouse (III) comprising a knockout mutation in a genomic mSal2 gene;

(5) a transgenic mouse (IV), whose genome comprises a nucleic acid construct including a Sal2 nucleic acid operably linked to transcriptional regulatory elements, encoding a Sal2 protein;

(6) a cell line derived from cells isolated from (IV); and

(7) identifying (M4) a compound which alters cell proliferation.

ACTIVITY - Cytostatic.

No biological data given.

MECHANISM OF ACTION - Lyses abnormally proliferating cells.

USE - M1 is useful for identifying a cellular protein involved in susceptibility to proliferative disease. (II) is useful for killing an abnormally proliferating cell. M3 is useful for identifying a mammal having a proliferative disease or for identifying a mammal at increased risk of acquiring a proliferative disease. (All claimed). (II) is useful for identifying genes altered in abnormally proliferative cells. The methods can be used to diagnose cancerous cells in a patient. (III) and (IV) are useful as research tools to determine genetic and physiological features of a cancer, and for identifying compounds that can affect ovarian and other tumors. The animals can also serve as a model system for assessing the risk of acquiring a proliferative disease that is associated with a particular mutation.

ADVANTAGE - The method is an undirected search using non-polyoma transformed or tumor-derived cells. The selection of virus mutants is therefore unbiased except for the possibility of being conditional on the transformed state of the particular permissive host being used. Thus the inventive strategy can lead to the identification of viral function and cellular targets not revealed by conventional genetic screens or co-immuno precipitation. The method also has a particular advantage over standard chemotherapy treatments, in that they are specific for cells with a proliferative disease. Hence, the therapy has fewer toxic side effects than the chemotherapeutic agents used.

ABSTRACTED-PUB-NO:

US20020147996A
EQUIVALENT-ABSTRACTS:

NOVELTY - Identifying (M1) a cellular protein (I) involved in susceptibility to proliferative disease, comprising infecting normally (C1) and abnormally proliferating (C2) cells with a collection of uncharacterized mutant viruses, identifying a mutant virus (MV), identifying a mutated gene or protein (MP) that allow MV to grow only on C2, and identifying (I) that interacts only with wild-type protein, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

(1) a tumor host range (T-HR) virus (II) isolated by M1;

(2) determining (M2) the presence or absence of an alteration in the genetic material of a cell by determining if a cell can act as a permissive host for the propagation of a characterized T-HR mutant (a tumor host range mutant viruses which are able to propagate only in abnormally proliferating cells);

(3) identifying (M3) a mammal having or at increased risk of acquiring a proliferative disease, by determining alteration in Sal2 nucleic acid or protein, of the mammal;

(4) a knockout mouse (III) comprising a knockout mutation in a genomic mSal2 gene;

(5) a transgenic mouse (IV), whose genome comprises a nucleic acid construct including a Sal2 nucleic acid operably linked to transcriptional regulatory elements, encoding a Sal2 protein;

(6) a cell line derived from cells isolated from (IV); and

(7) identifying (M4) a compound which alters cell proliferation.

ACTIVITY - Cytostatic.

No biological data given.

MECHANISM OF ACTION - Lyses abnormally proliferating cells.

USE - M1 is useful for identifying a cellular protein involved in susceptibility to

proliferative disease. (II) is useful for killing an abnormally proliferating cell. M3 is useful for identifying a mammal having a proliferative disease or for identifying a mammal at increased risk of acquiring a proliferative disease. (All claimed). (II) is useful for identifying genes altered in abnormally proliferative cells. The methods can be used to diagnose cancerous cells in a patient. (III) and (IV) are useful as research tools to determine genetic and physiological features of a cancer, and for identifying compounds that can affect ovarian and other tumors. The animals can also serve as a model system for assessing the risk of acquiring a proliferative disease that is associated with a particular mutation.

ADVANTAGE - The method is an undirected search using non-polyoma transformed or tumor-derived cells. The selection of virus mutants is therefore unbiased except for the possibility of being conditional on the transformed state of the particular permissive host being used. Thus the inventive strategy can lead to the identification of viral function and cellular targets not revealed by conventional genetic screens or co-immuno precipitation. The method also has a particular advantage over standard chemotherapy treatments, in that they are specific for cells with a proliferative disease. Hence, the therapy has fewer toxic side effects than the chemotherapeutic agents used.

NOVELTY - Identifying (M1) a cellular protein (I) involved in susceptibility to proliferative disease, comprising infecting normally (C1) and abnormally proliferating (C2) cells with a collection of uncharacterized mutant viruses, identifying a mutant virus (MV), identifying a mutated gene or protein (MP) that allow MV to grow only on C2, and identifying (I) that interacts only with wild-type protein, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

(1) a tumor host range (T-HR) virus (II) isolated by M1;

(2) determining (M2) the presence or absence of an alteration in the genetic material of a cell by determining if a cell can act as a permissive host for the propagation of a characterized T-HR mutant (a tumor host range mutant viruses which are able to propagate only in abnormally proliferating cells);

(3) identifying (M3) a mammal having or at increased risk of acquiring a proliferative disease, by determining alteration in Sal2 nucleic acid or protein, of the mammal;

(4) a knockout mouse (III) comprising a knockout mutation in a genomic mSal2 gene;

(5) a transgenic mouse (IV), whose genome comprises a nucleic acid construct including a Sal2 nucleic acid operably linked to transcriptional regulatory elements, encoding a Sal2 protein;

(6) a cell line derived from cells isolated from (IV); and

(7) identifying (M4) a compound which alters cell proliferation.

ACTIVITY - Cytostatic.

No biological data given.

MECHANISM OF ACTION - Lyses abnormally proliferating cells.

USE - M1 is useful for identifying a cellular protein involved in susceptibility to proliferative disease. (II) is useful for killing an abnormally proliferating cell. M3 is useful for identifying a mammal having a proliferative disease or for identifying a mammal at increased risk of acquiring a proliferative disease. (All claimed). (II) is useful for identifying genes altered in abnormally proliferative cells. The methods can be used to diagnose cancerous cells in a patient. (III) and (IV) are useful as research tools to determine genetic and physiological features of a cancer, and for identifying compounds that can affect ovarian and other tumors. The animals can also serve as a model system for assessing the risk of acquiring a proliferative disease that is associated with a particular mutation.

ADVANTAGE - The method is an undirected search using non-polyoma transformed or tumor-derived cells. The selection of virus mutants is therefore unbiased except for the possibility of being conditional on the transformed state of the particular permissive host being used. Thus the inventive strategy can lead to the identification

of viral function and cellular targets not revealed by conventional genetic screens or co-immuno precipitation. The method also has a particular advantage over standard chemotherapy treatments, in that they are specific for cells with a proliferative disease. Hence, the therapy has fewer toxic side effects than the chemotherapeutic agents used.

WO 200204596A

ABSTRACTED-PUB-NO: US20020018765A
EQUIVALENT-ABSTRACTS: NOVELTY - Identifying (M1) a cellular protein (I) involved in susceptibility to proliferative disease, comprising infecting normally (C1) and abnormally proliferating (C2) cells with a collection of uncharacterized mutant viruses, identifying a mutant virus (MV), identifying a mutated gene or protein (MP) that allow MV to grow only on C2, and identifying (I) that interacts only with wild-type protein, is new. DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following: (1) a tumor host range (T-HR) virus (II) isolated by M1; (2) determining (M2) the presence or absence of an alteration in the genetic material of a cell by determining if a cell can act as a permissive host for the propagation of a characterized T-HR mutant (a tumor host range mutant viruses which are able to propagate only in abnormally proliferating cells); (3) identifying (M3) a mammal having or at increased risk of acquiring a proliferative disease, by determining alteration in Sal2 nucleic acid or protein, of the mammal; (4) a knockout mouse (III) comprising a knockout mutation in a genomic mSal2 gene; (5) a transgenic mouse (IV), whose genome comprises a nucleic acid construct including a Sal2 nucleic acid operably linked to transcriptional regulatory elements, encoding a Sal2 protein; (6) a cell line derived from cells isolated from (IV); and (7) identifying (M4) a compound which alters cell proliferation. ACTIVITY - Cytostatic. No biological data given. MECHANISM OF ACTION - Lyses abnormally proliferating cells. USE - M1 is useful for identifying a cellular protein involved in susceptibility to proliferative disease. (II) is useful for killing an abnormally proliferating cell. M3 is useful for identifying a mammal having a proliferative disease or for identifying a mammal at increased risk of acquiring a proliferative disease. (All claimed). (II) is useful for identifying genes altered in abnormally proliferative cells. The methods can be used to diagnose cancerous cells in a patient. (III) and (IV) are useful as research tools to determine genetic and physiological features of a cancer, and for identifying compounds that can affect ovarian and other tumors. The animals can also serve as a model system for assessing the risk of acquiring a proliferative disease that is associated with a particular mutation. ADVANTAGE - The method is an undirected search using non-polyoma transformed or tumor-derived cells. The selection of virus mutants is therefore unbiased except for the possibility of being conditional on the transformed state of the particular permissive host being used. Thus the inventive strategy can lead to the identification of viral function and cellular targets not revealed by conventional genetic screens or co-immuno precipitation. The method also has a particular advantage over standard chemotherapy treatments, in that they are specific for cells with a proliferative disease. Hence, the therapy has fewer toxic side effects than the chemotherapeutic agents used. US20020147996A NOVELTY - Identifying (M1) a cellular protein (I) involved in susceptibility to proliferative disease, comprising infecting normally (C1) and abnormally proliferating (C2) cells with a collection of uncharacterized mutant viruses, identifying a mutant virus (MV), identifying a mutated gene or protein (MP) that allow MV to grow only on C2, and identifying (I) that interacts only with wild-type protein, is new. DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following: (1) a tumor host range (T-HR) virus (II) isolated by M1; (2) determining (M2) the presence or absence of an alteration in the genetic material of a cell by determining if a cell can act as a permissive host for the propagation of a characterized T-HR mutant (a tumor host range mutant viruses which are able to propagate only in abnormally proliferating cells); (3) identifying (M3) a mammal having or at increased risk of acquiring a proliferative disease, by determining alteration in Sal2 nucleic acid or protein, of the mammal; (4) a knockout mouse (III) comprising a knockout mutation in a genomic mSal2 gene; (5) a transgenic mouse (IV), whose genome comprises a nucleic acid construct including a Sal2 nucleic acid operably linked to transcriptional regulatory elements, encoding a Sal2 protein; (6) a cell line derived from cells isolated from (IV); and (7) identifying (M4) a compound which alters cell proliferation. ACTIVITY - Cytostatic. No biological data given. MECHANISM OF ACTION - Lyses abnormally proliferating cells. USE - M1 is useful for identifying a cellular protein involved in susceptibility to proliferative disease. (II) is useful for killing an abnormally proliferating cell. M3 is useful for identifying a mammal having a proliferative disease or for identifying a mammal at increased risk of acquiring a proliferative disease. (All claimed). (II) is useful for identifying genes altered in

abnormally proliferative cells. The methods can be used to diagnose cancerous cells in a patient. (III) and (IV) are useful as research tools to determine genetic and physiological features of a cancer, and for identifying compounds that can affect ovarian and other tumors. The animals can also serve as a model system for assessing the risk of acquiring a proliferative disease that is associated with a particular mutation. ADVANTAGE - The method is an undirected search using non-polyoma transformed or tumor-derived cells. The selection of virus mutants is therefore unbiased except for the possibility of being conditional on the transformed state of the particular permissive host being used. Thus the inventive strategy can lead to the identification of viral function and cellular targets not revealed by conventional genetic screens or co-immuno precipitation. The method also has a particular advantage over standard chemotherapy treatments, in that they are specific for cells with a proliferative disease. Hence, the therapy has fewer toxic side effects than the chemotherapeutic agents used. WO 200204596A

CHOSEN-DRAWING: Dwg.0/11

NCBI PubMed National Library of Medicine NLM

PubMed Nucleotide Protein Genome Structure PMC Taxonomy OMIM Bo

Search PubMed for Go Clear

Limits Preview/Index History Clipboard Details

Display Summary Show 20 Sort Send to Text

Items 1-20 of 370 Page 1 of 19 Next

Entrez PubMed

PubMed Services

Related Resources

1: Li D, Dower K, Ma Y, Tian Y, Benjamin TL. Related Articles, Links

A tumor host range selection procedure identifies p150(sal2) as a target of polyoma virus large T antigen.
Proc Natl Acad Sci U S A. 2001 Dec 4;98(25):14619-24.
PMID: 11734654 [PubMed - indexed for MEDLINE]

2: Freund R, Bronson RT, Benjamin TL. Related Articles, Links

Separation of immortalization from tumor induction with polyoma large T mutants that fail to bind the retinoblastoma gene product.
Oncogene. 1992 Oct;7(10):1979-87.
PMID: 1328987 [PubMed - indexed for MEDLINE]

3: Soderbarg K, Magnusson G. Related Articles, Links

Lytic functions of mutant polyomavirus large T-antigen with deletion of retinoblastoma protein-binding motif.
Virology. 1993 Mar;193(1):281-8.
PMID: 8382398 [PubMed - indexed for MEDLINE]

4: Garcea RL, Talmage DA, Harmatz A, Freund R, Benjamin TL. Related Articles, Links

Separation of host range from transformation functions of the hr-t gene of polyomavirus.
Virology. 1989 Feb;168(2):312-9.
PMID: 2536985 [PubMed - indexed for MEDLINE]

5: Rose PE, Schaffhausen BS. Related Articles, Links

Zinc-binding and protein-protein interactions mediated by the polyomavirus large T antigen zinc finger.
J Virol. 1995 May;69(5):2842-9.
PMID: 7707506 [PubMed - indexed for MEDLINE]

6: Freund R, Sotnikov A, Bronson RT, Benjamin TL. Related Articles, Links

Polyoma virus middle T is essential for virus replication and persistence as well as for tumor induction in mice.
Virology. 1992 Dec;191(2):716-23.
PMID: 1333120 [PubMed - indexed for MEDLINE]

7: Tang WJ, Folk WR. Related Articles, Links

Asp-286----Asn-286 in polyomavirus large T antigen relaxes the specificity of binding to the polyomavirus origin.
J Virol. 1989 Jan;63(1):242-9.
PMID: 2535730 [PubMed - indexed for MEDLINE]

8: Benjamin TL. Related Articles, Links

Polyoma virus: old findings and new challenges.
Virology. 2001 Oct 25;289(2):167-73. Review.
PMID: 11689038 [PubMed - indexed for MEDLINE]

9: Bergqvist A, Nilsson M, Bondeson K, Magnusson G. Related Articles, Links

Loss of DNA-binding and new transcriptional trans-activation function in polyomavirus large T-antigen with mutation of zinc finger motif.
Nucleic Acids Res. 1990 May 11;18(9):2715-20.
PMID: 2160069 [PubMed - indexed for MEDLINE]

10: Bendig MM, Thomas T, Folk WR. Related Articles, Links

Viable deletion mutant in the medium and large T-antigen-coding sequences of the polyoma virus genome.
J Virol. 1980 Mar;33(3):1215-20.
PMID: 6245272 [PubMed - indexed for MEDLINE]

11: Dalianis T. Related Articles, Links

Studies on the polyoma virus tumor-specific transplantation antigen (TSTA).
Adv Cancer Res. 1990;55:57-85. Review. No abstract available.
PMID: 1696775 [PubMed - indexed for MEDLINE]

12: Pilon AA, Mes-Masson AM. Related Articles, Links

Polyomavirus large T antigen zinc finger is not required for efficient cellular immortalization of primary rat embryo fibroblasts.
Virus Res. 1996 Dec;46(1-2):171-5.
PMID: 9029789 [PubMed - indexed for MEDLINE]

13: Linder S, Nilsson M, Martens I, Magnusson G. Related Articles, Links

A viable mouse polyomavirus mutant without immortalizing or transforming activities.
Virology. 1990 Nov;179(1):78-86.
PMID: 2171224 [PubMed - indexed for MEDLINE]

14: Nilsson SV, Magnusson G. Related Articles, Links

Activities of polyomavirus large-T-antigen proteins expressed by mutant genes.
J Virol. 1984 Sep;51(3):768-75.
PMID: 6088799 [PubMed - indexed for MEDLINE]

15: Reinholdsson G, Ramqvist T, Brandberg J, Dalianis T. Related Articles, Links

A polyomavirus tumor-specific transplantation antigen (TSTA) epitope is situated within the N-terminal amino acid sequence common to middle and small T-antigens.
Virology. 1988 Oct;166(2):616-9.
PMID: 2459846 [PubMed - indexed for MEDLINE]

16: Dilworth SM, Cowie A, Kamen RI, Griffin BE. Related Articles, Links

DNA binding activity of polyoma virus large tumor antigen.
Proc Natl Acad Sci U S A. 1984 Apr;81(7):1941-5.
PMID: 6326093 [PubMed - indexed for MEDLINE]

17: Dalianis T, Ramqvist T, Klein G. Related Articles, Links

Studies on the polyoma-virus-induced tumor-specific transplantation antigen (TSTA)--does middle or large T-antigen play a role?
Int J Cancer. 1984 Sep 15;34(3):403-6.
PMID: 6090322 [PubMed - indexed for MEDLINE]

18: Freund R, Bauer PH, Crissman HA, Bradbury EM, Benjamin TL. Related Articles, Links

Host range and cell cycle activation properties of polyomavirus large T-antigen mutants defective in pRB binding.
J Virol. 1994 Nov;68(11):7227-34.
PMID: 7933105 [PubMed - indexed for MEDLINE]

19: St-Onge L, Bastin M. Related Articles, Links

Amplification mediated by polyomavirus large T antigen defective in replication.
J Virol. 1993 Aug;67(8):5025-9.
PMID: 8392627 [PubMed - indexed for MEDLINE]

20: Yi X, Peterson J, Freund R. Related Articles, Links

Transformation and tumorigenic properties of a mutant polyomavirus containing a middle T antigen defective in Shc binding.
J Virol. 1997 Sep;71(9):6279-86.
PMID: 9261344 [PubMed - indexed for MEDLINE]

Display Summary Show: 20 Sort Send to Text

Items 1-20 of 370 Page 1 of 19 Next

Write to the Help Desk
NCBI | NLM | NIH
Department of Health & Human Services
Freedom of Information Act | Disclaimer

Jul 8 2003 10:56:01

NCBI PubMed National Library of Medicine NLM

PubMed Nucleotide Protein Genome Structure PMC Taxonomy OMIM Bo

Search PubMed for Benjamin TL Go Clear

Limits Preview/Index History Clipboard Details

Display Summary Show: 20 Sort Send to Text

Items 1-20 of 85 Page 1 of 5 Next

Entrez PubMed

PubMed Services

Related Resources

1: Gilbert JM, Goldberg IG, Benjamin TL. Related Articles, Links

Cell penetration and trafficking of polyomavirus.
J Virol. 2003 Feb;77(4):2615-22.
PMID: 12552000 [PubMed - indexed for MEDLINE]

2: Velupillai P, Carroll JP, Benjamin TL. Related Articles, Links

Susceptibility to polyomavirus-induced tumors in inbred mice: role of innate immune responses.
J Virol. 2002 Oct;76(19):9657-63.
PMID: 12208944 [PubMed - indexed for MEDLINE]

3: Dey D, Dahl J, Cho S, Benjamin TL. Related Articles, Links

Induction and bypass of p53 during productive infection by polyomavirus.
J Virol. 2002 Sep;76(18):9526-32.
PMID: 12186934 [PubMed - indexed for MEDLINE]

4: Li D, Dower K, Ma Y, Tian Y, Benjamin TL. Related Articles, Links

A tumor host range selection procedure identifies p150(sal2) as a target of polyoma virus large T antigen.
Proc Natl Acad Sci U S A. 2001 Dec 4;98(25):14619-24.
PMID: 11734654 [PubMed - indexed for MEDLINE]

5: Benjamin TL. Related Articles, Links

Polyoma virus: old findings and new challenges.
Virology. 2001 Oct 25;289(2):167-73. Review.
PMID: 11689038 [PubMed - indexed for MEDLINE]

6: Cho S, Tian Y, Benjamin TL. Related Articles, Links

Binding of p300/CBP co-activators by polyoma large T antigen.
J Biol Chem. 2001 Sep 7;276(36):33533-9. Epub 2001 Jul 03.
PMID: 11438528 [PubMed - indexed for MEDLINE]

7: Gilbert JM, Benjamin TL. Related Articles, Links

Early steps of polyomavirus entry into cells.
J Virol. 2000 Sep;74(18):8582-8.
PMID: 10954560 [PubMed - indexed for MEDLINE]

8: Dey DC, Bronson RP, Dahl J, Carroll JP, Benjamin TL. Related Articles, Links

Accelerated development of polyoma tumors and embryonic lethality: different effects of p53 loss on related mouse backgrounds.
Cell Growth Differ. 2000 May;11(5):231-7.
PMID: 10845423 [PubMed - indexed for MEDLINE]

9: Velupillai P, Yoshizawa I, Dey DC, Nahill SR, Carroll JP, Bronson RT, Benjamin TL. Related Articles, Links

Wild-derived inbred mice have a novel basis of susceptibility to polyomavirus-induced tumors.
J Virol. 1999 Dec;73(12):10079-85.
PMID: 10559322 [PubMed - indexed for MEDLINE]

10: Bauer PH, Cui C, Liu R, Stehle T, Harrison SC, DeCaprio JA, Benjamin TL. Related Articles, Links

Discrimination between sialic acid-containing receptors and pseudoreceptors regulates polyomavirus spread in the mouse.
J Virol. 1999 Jul;73(7):5826-32. Erratum in: J Virol 2000 Jun;74(12):5746.
PMID: 10364334 [PubMed - indexed for MEDLINE]

11: Carroll JP, Fung JS, Bronson RT, Razvi E, Benjamin TL. Related Articles, Links

Radiation-resistant and radiation-sensitive forms of host resistance to polyomavirus.
J Virol. 1999 Feb;73(2):1213-8.
PMID: 9882323 [PubMed - indexed for MEDLINE]

12: Dahl J, Jurczak A, Cheng LA, Baker DC, Benjamin TL. Related Articles, Links

Evidence of a role for phosphatidylinositol 3-kinase activation in the blocking of apoptosis by polyomavirus middle T antigen.
J Virol. 1998 Apr;72(4):3221-6.
PMID: 9525648 [PubMed - indexed for MEDLINE]

13: Cullere X, Rose P, Thathamangalam U, Chatterjee A, Mullane KP, Pallas DC, Benjamin TL, Roberts TM, Schaffhausen BS. Related Articles, Links

Serine 257 phosphorylation regulates association of polyomavirus middle T antigen with 14-3-3 proteins.
J Virol. 1998 Jan;72(1):558-63.
PMID: 9420259 [PubMed - indexed for MEDLINE]

14: Bauer PH, Benjamin TL. Related Articles, Links

A novel 39-kilodalton membrane protein binds GTP in polyomavirus-transformed cells.
J Virol. 1997 May;71(5):4128-32.
PMID: 9094695 [PubMed - indexed for MEDLINE]

15: Dahl J, Freund R, Blenis J, Benjamin TL. Related Articles, Links

Studies of partially transforming polyomavirus mutants establish a role for phosphatidylinositol 3-kinase in activation of pp70 S6 kinase.
Mol Cell Biol. 1996 Jun;16(6):2728-35.
PMID: 8649380 [PubMed - indexed for MEDLINE]

☐ **16:** Young AT, Dahl J, Hausdorff SF, Bauer PH, Birnbaum MJ, Benjamin TL. Related Articles, Links

Phosphatidylinositol 3-kinase binding to polyoma virus middle tumor antigen mediates elevation of glucose transport by increasing translocation of the GLUT1 transporter.
Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11613-7. Erratum in: Proc Natl Acad Sci U S A 1996 Jan 23;93(2):961.
PMID: 8524814 [PubMed - indexed for MEDLINE]

☐ **17:** Bauer PH, Bronson RT, Fung SC, Freund R, Stehle T, Harrison SC, Benjamin TL. Related Articles, Links

Genetic and structural analysis of a virulence determinant in polyomavirus VP1.
J Virol. 1995 Dec;69(12):7925-31.
PMID: 7494305 [PubMed - indexed for MEDLINE]

☐ **18:** Lukacher AE, Ma Y, Carroll JP, Abromson-Leeman SR, Laning JC, Dorf ME, Benjamin TL. Related Articles, Links

Susceptibility to tumors induced by polyoma virus is conferred by an endogenous mouse mammary tumor virus superantigen.
J Exp Med. 1995 May 1;181(5):1683-92.
PMID: 7722447 [PubMed - indexed for MEDLINE]

☐ **19:** Freund R, Bauer PH, Crissman HA, Bradbury EM, Benjamin TL. Related Articles, Links

Host range and cell cycle activation properties of polyomavirus large T-antigen mutants defective in pRB binding.
J Virol. 1994 Nov;68(11):7227-34.
PMID: 7933105 [PubMed - indexed for MEDLINE]

☐ **20:** Stehle T, Yan Y, Benjamin TL, Harrison SC. Related Articles, Links

Structure of murine polyomavirus complexed with an oligosaccharide receptor fragment.
Nature. 1994 May 12;369(6476):160-3.
PMID: 8177322 [PubMed - indexed for MEDLINE]

Display Summary Show: 20 Sort Send to Text

Items 1-20 of 85 Page 1 of 5 Next